Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
Boston, Massachusetts, United States In 2006 was created MP Healthcare Venture Management, which is appeared as VC. The leading representative office of defined VC is situated in the Boston. The venture was found in North America in United States.
We also calculated 1 valuable employee in our database.
The fund has no exact preference in a number of founders of portfolio startups. If startup sums 2 or 4 of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Thrasos, Genkyotex, Covagen For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the MP Healthcare Venture Management, startups are often financed by Atlas Venture, SR One, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are SR One, M Ventures, Atlas Venture. In the next rounds fund is usually obtained by SR One, Andera Partners, Ventech.
The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2014. The high activity for fund was in 2009. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 16 percentage points less often commits exit comparing to other organizations. This MP Healthcare Venture Management works on 0 percentage points less the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.
Funds with similar focus
| Fund Name | Location |
| Applied Technologies Company | Moscow, Moscow, Russia |
| Arancia International | Guadalajara, Jalisco, Mexico |
| Ascenion GmbH | - |
| BASF Canada | Canada, Ontario, Windsor |
| East of England Co-operative Society Limited | - |
| Enable Capital Management | California, San Francisco, United States |
| GPS Ventures GmbH | Berlin, Berlin, Germany |
| Guanrong Touzi | China, Guangdong, Shenzhen |
| Jan Cieslikiewicz Ventures | Brooklyn, New York, United States |
| KCB Group | Kenya, Nairobi, Nairobi Area |
| Marin Investments | British Columbia, Canada, Vancouver |
| Matsui Securities | Chiyoda, Japan |
| Michigan Rise | - |
| Newsinvest | France, Ile-de-France, Paris |
| Shin Nippon Biomedical Laboratories (SNBL) | Chiyoda, Japan |
| Suzhou Nongfa Chuangxin | China, Jiangsu, Suzhou |
| Tiansheng | China, Jinhua, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Korro Bio | $116M | 05 Jan 2022 | Cambridge, Massachusetts, United States | ||
Libero Thera | $4M | 14 May 2021 | Chuo, Japan | ||
Blacksmith Medicines | 08 Jan 2021 | San Diego, California, United States | |||
Korro Bio | $91M | 10 Sep 2020 | Cambridge, Massachusetts, United States | ||
QurAlis | $42M | 13 May 2020 | Cambridge, Massachusetts, United States | ||
Ribometrix | $7M | 27 Sep 2019 | Greenville, South Carolina, United States | ||
Sonde Health | $16M | 11 Apr 2019 | Boston, Massachusetts, United States | ||
QurAlis | $5M | 19 Nov 2018 | Cambridge, Massachusetts, United States | ||
Ribometrix | $30M | 13 Nov 2018 | Greenville, South Carolina, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
